BioMed Research International / 2014 / Article / Tab 8

Review Article

Implications of Heterogeneity in Multiple Myeloma

Table 8

Summary of agents in development which may be selectively toxic to MPC.

Drug/moleculeMechanism of actionPhase/used in combination with other agents

DZNep inhibitorDisruption of PRC2 Preclinical
Vimodegib (GDC-0449)Hedgehog signaling inhibitorPhase I/after auto SCT
R0490927NOTCH signaling inhibitorPhase II/melphalan
MK571 MRP3 inhibitorPreclinical/bortezomib
ATRAInduces degradation of RARα2Preclinical
ImetelstatTelomerase InhibitorPreclinical
NK cell therapyCellular cytotoxicityPreclinical

SCT = Stem cell transplant.